Losigamone (cas 112856-44-7) a putative antiepileptic drug

Add time:07/27/2019    Source:sciencedirect.com

Losigamone (cas 112856-44-7) (LSG) has shown anticonvulsant efficacy and low neurotoxicity in preclinical testing and has been tolerated in Phase I clinical trials. We report an open-label, add-on tolerability study of six ascending LSG dosage levels from 600 to 2,100 mg daily in patients receiving phenytoin (PHT), carbamazepine (CBZ), or combination PHT/CBZ. Dosage was escalated weekly, with assessment including reports of adverse events (AE), seizure diary, neurologic and physical examination, electrocardiogram (ECG), and laboratory tests. No serious AE were reported, and those most common AE were headache and dizziness. No significant alteration in PHT, CBZ, or CBZ-epoxide (CBZ-E) levels was noted. No clinically significant change in laboratory tests was noted. A median seizure reduction during LSG treatment as compared with baseline of 39% was achieved during the study. All 9 patients continued into an extension study, and 3 have remained seizure-free for as long as 2 years. Some brief increases in seizure frequency were evident at the 1,800- and 2,100-mg daily dosage levels. We conclude that continued evaluation of LSG for the treatment of partial seizures is indicated.

We also recommend Trading Suppliers and Manufacturers of Losigamone (cas 112856-44-7). Pls Click Website Link as below: cas 112856-44-7 suppliers

Prev:Losigamone (cas 112856-44-7) decreases spontaneous synaptic activity in cultured hippocampal neurons
Next:Effects of Losigamone (cas 112856-44-7) on synaptic potentials and spike frequency habituation in rat entorhinal cortex and hippocarnpal CA1 neurones)